Lack of Pre-antiretroviral Care and Competition from Traditional Healers, Crucial Risk Factors for Very Late Initiation of Antiretroviral Therapy for HIV--a Case-control Study from Eastern Uganda
Overview
Authors
Affiliations
Background: Although WHO recommends starting antiretroviral treatment at a CD4 count of 350 cells/[µ]L, many Ugandan districts still struggle with large proportions of clients initiating ART very late at CD4<50 cells/[µ]L. This study seeks to establish crucial risk factors for very late ART initiation in eastern Uganda.
Methods: All adult HIV-infected clients on ART in Iganga who enrolled between 2005 and 2009 were eligible for this case-control study. Clients who started ART at CD4 cell count of <50 cells/[µ]L (very late initiators) were classified as cases and 50-200 cells/[µ]L (late initiators) as control subjects. A total of 152 cases and 202 controls were interviewed. Multivariate analyses were performed to calculate adjusted odds ratios and 95% confidence intervals.
Results: Reported health system-related factors associated with very late ART initiation were stock-outs of antiretroviral drugs stock-outs (affecting 70% of the cases and none of the controls), competition from traditional/spiritual healers (AOR 7.8, 95 CI% 3.7-16.4), and lack of pre-ARV care (AOR 4.6, 95% CI: 2.3-9.3). Men were 60% more likely and subsistence farmers six times more likely (AOR 6.3, 95% CI: 3.1-13.0) to initiate ART very late. Lack of family support tripled the risk of initiating ART very late (AOR 3.3, 95% CI: 1.6-6.6).
Conclusion: Policy makers should prevent ARV stock-outs though effective ARV procurement and supply chain management. New HIV clients should seek pre-ARV care for routine monitoring and determination of ART eligibility. ART services should be more affordable, accessible and user-friendly to make them more attractive than traditional healers.
Ochen A, Lubogo D, Ediau M, Nankabirwa V PLOS Glob Public Health. 2023; 2(8):e0000691.
PMID: 36962456 PMC: 10021445. DOI: 10.1371/journal.pgph.0000691.
Wiginton J, Mathur S, Gottert A, Pilgrim N, Pulerwitz J Front Public Health. 2022; 10:861431.
PMID: 35651865 PMC: 9149263. DOI: 10.3389/fpubh.2022.861431.
Gebru T, Lentiro K, Jemal A BMC Res Notes. 2018; 11(1):336.
PMID: 29789010 PMC: 5964917. DOI: 10.1186/s13104-018-3408-4.
Ruzagira E, Grosskurth H, Kamali A, Baisley K J Int AIDS Soc. 2017; 20(2).
PMID: 29052344 PMC: 5810339. DOI: 10.1002/jia2.25014.
Ruzagira E, Baisley K, Kamali A, Grosskurth H Contemp Clin Trials Commun. 2017; 5:56-62.
PMID: 28424795 PMC: 5389341. DOI: 10.1016/j.conctc.2016.12.003.